Product Description
Mechanisms of Action: DBH Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bial
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension
Phase 1: Heart Failure, Chronic|Hypertension|Hypertension, Pulmonary|Heart Failure|Pulmonary Heart Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BIA-51058-202 | P2 |
Completed |
Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension |
2022-02-17 |
24% |
| 2018-002796-18 | P2 |
Completed |
Hypertension, Pulmonary |
2022-02-17 |
|
| BIA-51058-201 | P2 |
Completed |
Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension |
2021-10-20 |
|
| Pharmacokinetics, safety and efficacy of BIA 5-1058 in PAH | P2 |
Completed |
Hypertension, Pulmonary |
2021-10-20 |